89 assets in Prostate Adenocarcinoma

Therapeutic assets addressing Prostate Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Mevrometostat Prostate Adenocarcinoma	Prostate Cancer Clinical Trials Consortium	P2	CCC (53)
Sacituzumab Tirumotecan Prostate Adenocarcinoma	Tianjin Medical University Second Hospital	P2	CCC (53)
Tagitanlimab Prostate Adenocarcinoma	Tianjin Medical University Second Hospital	P2	CCC (53)
Valaciclovir Prostate Adenocarcinoma	Candel Therapeutics, Inc.	P2	CCC (53)
Vandazole Prostate Adenocarcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Vipivotide Tetraxetan Gallium Ga-68 Prostate Adenocarcinoma	University of Washington	P2	CCC (53)
68ga-hbed-ipsma Prostate Adenocarcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (51)
Aspirin Prostate Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (51)
Epigallocatechin-3-Gallate Prostate Adenocarcinoma	H. Lee Moffitt Cancer Center and Research Institute	P2	CCC (51)
Etrumadenant Prostate Adenocarcinoma	David Oh	P2	CCC (51)
Flibanserin Prostate Adenocarcinoma	Andrew McDonald	P2	CCC (51)
Fluorine (18F) Psma 1007 Prostate Adenocarcinoma	Glenn Bauman	P2	CCC (51)
Furosemide Prostate Adenocarcinoma	Emory University	P2	CCC (51)
Golimumab Prostate Adenocarcinoma	University of Washington	P2	CCC (51)
Interferon Alfa-2B Prostate Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (51)
Lutetium (<Sup>177</Sup>Lu) Zadavotide Guraxetan Prostate Adenocarcinoma	Jonsson Comprehensive Cancer Center	P2	CCC (51)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Prostate Adenocarcinoma	University of Chicago	P2	CCC (51)
Tislelizumab Prostate Adenocarcinoma	SOLTI Breast Cancer Research Group	P2	CCC (51)
Tocilizumab Prostate Adenocarcinoma	David Oh	P2	CCC (51)
68ga-p16-093 Prostate Adenocarcinoma	First Affiliated Hospital of Fujian Medical University	P1/2	CCC (48)
Rintatolimod Prostate Adenocarcinoma	Roswell Park Cancer Institute	P2	CCC (48)
Pyruvate Prostate Adenocarcinoma	M.D. Anderson Cancer Center	P2	CC (47)
Spartalizumab Prostate Adenocarcinoma	SOLTI Breast Cancer Research Group	P2	CC (46)
68ga-g21 Prostate Adenocarcinoma	First Affiliated Hospital of Fujian Medical University	P1/2	CC (45)
68ga-g23 Prostate Adenocarcinoma	First Affiliated Hospital of Fujian Medical University	P1/2	CC (45)
Abemaciclib Prostate Adenocarcinoma	Vadim S Koshkin	P1/2	CC (45)
Anti-Steap1 Car T-Cells Prostate Adenocarcinoma	Fred Hutchinson Cancer Center	P1/2	CC (45)
as1986ns Prostate Adenocarcinoma	Antelope Surgical Solutions, Inc	P1/2	CC (45)
Bms 986253 Prostate Adenocarcinoma	Mark Stein	P1/2	CC (45)
Ruxolitinib Prostate Adenocarcinoma	University of Michigan Rogel Cancer Center	P1/2	CC (45)
Etb-Dualnk-01 Prostate Adenocarcinoma	Beijing Biotech	P1	CC (43)
Ace-232 Tablets Prostate Adenocarcinoma	Acerand Therapeutics (Hong Kong) Limited	P1	CC (41)
Masofaniten Prostate Adenocarcinoma	Pedro Barata, MD, MSc	P2	CC (41)
Copper 61-Psma Pet/Ct Prostate Adenocarcinoma	Hoag Memorial Hospital Presbyterian	P1	C (39)
Immunoglobulin G1 [De-448-Lysine], Anti-(Human Epidermal Growth Factor Receptor) (Human-Mouse Monoclonal C225 ?1-Chain) Fusion Protein With Peptide Linker (Ggggs)2 Fusion Protein With Immunoglobulin Anti-(Human Epidermal Growth Factor Receptor Her3) (Human Clone Her3.H3 Single-Chain Variable Fragment Vh-(Ggggs)3-Vl), Complex With Human-Mouse Monoclonal C225 ?-Chain, Dimer, 214??,214???,222,222?,228,228?,231,231?-Octakis(Thioether) With (2S)-N-(Carboxymethyl)-2-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-?-Alanylglycylglycyl-L-Phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-1-Methyl-2-Oxoethoxy]Methyl]Glycinamide Prostate Adenocarcinoma	SystImmune Inc.	P1	C (39)
Lutetium Lu 177 Psma-10.1 Prostate Adenocarcinoma	Emory University	P1	C (39)
NORVIR Prostate Adenocarcinoma	University of Chicago	P1	C (39)
68Ga-AAZTA-NI-093 Prostate Adenocarcinoma	First Affiliated Hospital of Fujian Medical University	Early P1	C (38)
Vudalimab Prostate Adenocarcinoma	Emory University	P1	C (37)

Showing 51 to 89 of 89 assets

PreviousPage 2 of 2Next